CADM4, cell adhesion molecule 4, 199731

N. diseases: 27; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 Biomarker disease BEFREE CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers including prostate cancer. 21062931 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 Biomarker disease BEFREE TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1. 16261159 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.030 AlteredExpression disease BEFREE Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers. 11536053 2001
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 Biomarker disease BEFREE CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers including prostate cancer. 21062931 2010
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 Biomarker disease BEFREE TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1. 16261159 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 AlteredExpression disease BEFREE Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers. 11536053 2001
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE While it has been reported that inactivation of CADM1 and CADM4 serves a pivotal role in the progression of breast cancer, a full analysis has not been completed for TNBC. 30655848 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE The prognostic role of CADM1 and CADM4 in breast cancer was also evaluated and the expression of CADM1 and CADM4 were not associated with cancer-specific survival or overall survival rate in the cohort of patients in the present study. 29434950 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE While it has been reported that inactivation of CADM1 and CADM4 serves a pivotal role in the progression of breast cancer, a full analysis has not been completed for TNBC. 30655848 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE The prognostic role of CADM1 and CADM4 in breast cancer was also evaluated and the expression of CADM1 and CADM4 were not associated with cancer-specific survival or overall survival rate in the cohort of patients in the present study. 29434950 2018
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.020 AlteredExpression disease BEFREE On multivariate analysis, SIA in the jejunum and ileum, (hazard ratio [HR], 2.465; 95% confidence interval [CI], 1.288-4.720; p = 0.006 and HR, 3.407; 95% CI, 1.515-7.662; p = 0.003, respectively), signet ring cell carcinoma (HR, 92.388; 95% CI, 14.813-576.230; p = 0.000), SIA with lymph node metastasis (HR, 3.223; 95% CI, 1.697-6.124; p = 0.000), retroperitoneal seeding (HR, 3.696; 95% CI, 1.303-10.479; p = 0.014), and CADM4 expression loss (HR, 2.348; 95% CI, 1.130-4.882; p = 0.022) were associated with poor OS. 28444978 2017
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.020 AlteredExpression disease BEFREE Negative Necl-4 expression was significantly associated with a larger tumour size of >30 mm, perineural invasion, lymphatic involvement, lymph node metastasis (pN1), an advanced TNM (tumour, node, metastases) stage (stage IIB-IV), an advanced histological grade (G2/3), and shorter overall survival. 27980052 2017
CUI: C0017638
Disease: Glioma
Glioma 		0.010 AlteredExpression disease BEFREE Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers. 11536053 2001
CUI: C0023492
Disease: Leukemia, T-Cell
Leukemia, T-Cell 		0.010 Biomarker disease BEFREE SPRi analysis identified a new interaction between CADM1 and CADM4, where this heterophilic interaction was shown to be involved in morphological spreading of adult T-cell leukemia (ATL) cells expressing CADM1 when incubated on CADM4-coated glass. 30131958 2018
CUI: C0023493
Disease: Adult T-Cell Lymphoma/Leukemia
Adult T-Cell Lymphoma/Leukemia 		0.010 Biomarker disease BEFREE SPRi analysis identified a new interaction between CADM1 and CADM4, where this heterophilic interaction was shown to be involved in morphological spreading of adult T-cell leukemia (ATL) cells expressing CADM1 when incubated on CADM4-coated glass. 30131958 2018
CUI: C0206696
Disease: Carcinoma, Signet Ring Cell
Carcinoma, Signet Ring Cell 		0.010 GeneticVariation disease BEFREE On multivariate analysis, SIA in the jejunum and ileum, (hazard ratio [HR], 2.465; 95% confidence interval [CI], 1.288-4.720; p = 0.006 and HR, 3.407; 95% CI, 1.515-7.662; p = 0.003, respectively), signet ring cell carcinoma (HR, 92.388; 95% CI, 14.813-576.230; p = 0.000), SIA with lymph node metastasis (HR, 3.223; 95% CI, 1.697-6.124; p = 0.000), retroperitoneal seeding (HR, 3.696; 95% CI, 1.303-10.479; p = 0.014), and CADM4 expression loss (HR, 2.348; 95% CI, 1.130-4.882; p = 0.022) were associated with poor OS. 28444978 2017
CUI: C0270911
Disease: Charcot-Marie-Tooth Disease, Type Ia (disorder)
Charcot-Marie-Tooth Disease, Type Ia (disorder) 		0.010 Biomarker disease BEFREE We show an increase in the expression of MAG and a strong decrease of Necl4 in biopsies of CMT1A patients as well as in CMT1A mice. 22940629 2013
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.010 Biomarker disease BEFREE These findings suggest that CADM4 is a novel tumor suppressor candidate in RCCC acting with its binding partner 4.1B. 21544807 2012
CUI: C1301034
Disease: Pancreatic intraepithelial neoplasia
Pancreatic intraepithelial neoplasia 		0.010 AlteredExpression disease BEFREE The number of cases with positive Necl-4 expression decreased in the order low-grade PanIN>high-grade PanIN>PDAC (p<0.001). 27980052 2017
CUI: C1335302
Disease: Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma 		0.010 AlteredExpression disease BEFREE We investigated the clinicopathological significance of Necl-4 expression in patients with pancreatic ductal adenocarcinoma (PDAC). 27980052 2017
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.010 AlteredExpression disease BEFREE The number of cases with positive Necl-4 expression decreased in the order low-grade PanIN>high-grade PanIN>PDAC (p<0.001). 27980052 2017
CUI: C2216702
Disease: malignant neoplasm of breast staging
malignant neoplasm of breast staging 		0.010 AlteredExpression disease BEFREE Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer. 29434950 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.010 AlteredExpression disease BEFREE In the present study, CADM1 and CADM4 expression was evaluated in patients with TNBC who had received PST. 30655848 2019
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.010 AlteredExpression disease BEFREE In the present study, CADM1 and CADM4 expression was evaluated in patients with TNBC who had received PST. 30655848 2019
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.030 AlteredExpression phenotype BEFREE Loss of or low CADM4 expression was observed in 26 (15.3%) and 50 (29.4%) cases, respectively, and it was significantly associated with undifferentiated histology (p < 0.044), high-grade tumor (p < 0.001), high pT3 or pT4 stage (p < 0.038), pancreatic invasion (p < 0.018), and lymphatic invasion (p < 0.020). 28444978 2017